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We evaluated the genetic contribution of the T cellerestricted intracellular antigen-1 gene (TIA1) in a
European cohort of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) patients.
Exonic resequencing of TIA1 in 1120 patients (693 FTD, 341 ALS, 86 FTD-ALS) and 1039 controls identiﬁed
in total 5 rare heterozygous missense variants, affecting the TIA1 low-complexity domain (LCD). Only 1
missense variant, p.Met290Thr, identiﬁed in a familial FTD patient with disease onset at 64 years, was
absent from controls yet received a combined annotation-dependent depletion score of 11.42. By
contrast, 3 of the 4 variants also detected in unaffected controls, p.Val294Glu, p.Gln318Arg, and
p.Ala381Thr, had combined annotation-dependent depletion scores greater than 20. Our ﬁndings in a
large European patient-control series indicate that variants in TIA1 are not a common cause of ALS and
FTD. The observation of recurring TIA1 missense variants in unaffected individuals lead us to conclude
that the exact genetic contribution of TIA1 to ALS and FTD pathogenesis remains to be further elucidated.
 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Exome sequencing in an unresolved European amyotrophic
lateral sclerosis (ALS)efrontotemporal dementia (FTD) family with
transactive response DNA-binding protein-43 (TDP-43) brain pa-
thology identiﬁed a co-segregation missense mutation in the low-
complexity domain (LCD) of the T cellerestricted intracellular
antigen-1 gene (TIA1), affecting stress granule dynamics
(Mackenzie et al., 2017). Subsequent genetic screening revealed 6
additional rare missense mutations affecting the LCD in 3 unrelated
ALS and 2 ALS-FTD patients, all absent from controls, giving an
overall mutation frequency ofw2% familial ALS and<0.5% sporadic
ALS (Mackenzie et al., 2017). Aiming to replicate the reported ge-
netic association of TIA1with ALS and ALS-FTD, we set up a genetic
screen of TIA1 in a European case-control series of ALS-FTD spec-
trum patients, also including pure FTD patients.
2. Materials and methods
We sequenced the entire TIA1 coding region (exons 1e13) in a total
of 1120 patients and 1039 controls originating fromdifferent European
countries (detailed methodology description and ethical assurance
provided in Supplementary Material). The patient cohorts were
recruited in the framework of the Belgian Neurology (BELNEU)ollowing neurologist of the
nd pathological phenotyping
eman, Dirk Nuytten (Hospital
e Bleecker, Patrick Santens
ichotte (University Hospital
ty Hospital, Brussels); Olivier
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hat were included in the EU
y, Department of Diagnostics,
eurodegenerative Disorders,
ental Sciences, University of
oscience, Psychology, Drug
orence, Italy); Camilla Ferrari
es do Couto, Ana Verdelho,
University of Lisbon, Lisbon,Consortium, the European Early-Onset Dementia (EU EOD) Con-
sortium, and the Tübingen FTD Exome series, as described
(Blauwendraat et al., 2017; van der Zee et al., 2013; van der Zee et al.,
2017). DNA and medical/demographic information was included on
all patients, comprising 693 patients diagnosedwith FTD, 341 patients
with ALS, and 86 patients with concomitant FTD and ALS (FTD-ALS).
3. Results
We identiﬁed a total of 5 rare (minor allele frequency [MAF]
<1%) heterozygous missense variants, with only 1 variant
(p.Met290Thr) absent from the control cohort (Fig. 1, and
Supplementary Material Table S1). All 5 missense variants mapped
to the conserved TIA1 LCD region (exons 11e13).
The p.Met290Thr (rs116707801) was present in an Italian familial
FTDpatient (age atonset 64 years, age atdeath67 years). In ExACNFE,
this variant is counted 3 times in 66,732 alleles and has a combined
annotation-dependent depletion (CADD) score of 11.42. The second
missense variant identiﬁed in patients, p.Val294Glu (rs769199100),
was present in an isolated Italian ALS patient (onset age 39 years). It
was reported only once in 66,732 alleles of the ExACNFE data set and
received a CADD score of 20.9. However, we also observed the
p.Val294Glu variant in one of our 1039 control individuals, also from
Italian origin (age at inclusion 58 years). Furthermore, we detected a
heterozygous missense variant p.Ala381Thr (rs768554955) in
another Italian control individual (age at inclusion 70 years). The
p.Ala381Thr variant was observed once in 66,740 alleles in ExAC NFE
(MAF 0.001%) with a CADD score of 22.4.
In addition to these rare coding variants, we detected 2 recurring
missense variants with ExAC NFE MAFs just below 1%. The
p.Gln318Arg (rs115611153) variant was present in 15 patients and
29 controls. Despite its recurrent presence in unaffected in-
dividuals, it was scored among the 1% most deleterious variants in
the genome, with a CADD score of 23.5. The p.Asn357Ser
(rs116621885) variant was present in 14 patient and 18 controls,
and had a CADD score of 14.25.
No further low-frequency or common variants were detected.
4. Discussion
We evaluated the genetic contribution of TIA1 in 693 FTD, 341
ALS, and 86 ALS-FTD patients, including 80 patients with
Fig. 1. Schematic representation of TIA1 gene structure and protein with identiﬁed coding variants. Illustrated are the genomic region of TIA1 exon 11-13 encoding for the low
complexity domain (LCD). Variants identiﬁed in the present study are listed on top of the LCD structure; bold: patient-speciﬁc variant detected in a FTD patient, others: variants also
detected in control individuals. Below the LCD structure, amino acid residues encoded by the respective exons and previously reported variants in ALS or ALS-FTD patients
(Mackenzie et al., 2017; Yuan et al., 2017), as well as the Glu384Lys mutation identiﬁed in Welander distal myopathy (in italics) (Klar et al., 2013).
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et al., we did not identify any variants outside the LCD region. Only 1
variant was present in patients only, the other 4 were also observed
in unaffected controls.
The patient-speciﬁc variant p.Met290Thr was observed in 1 male
familial FTD patient of 693 FTDs (0.14%) and absent from a well-
characterized control cohort of 1039 individuals. The CADD score
however was signiﬁcantly less than 20, indicating it is less likely to
have a deleterious effect on protein function and explain the disease
phenotype of the patient. In the absence of supportive co-segregation
and functional evidence, we propose to classify this variant as variant
of uncertain signiﬁcance.We identiﬁed a female sporadic ALS patient
with early disease onset of 34 years with a p.Val294Glu variant clas-
siﬁed as deleterious by a CADD score of 20.9. However, we also
detected the same variant in 1male control individual of 58 years old.
Of interest is that a different amino acid change at the same codon
position (p.Val294Met, CADD score 22.3) was reported in an ALS
patient by Mackenzie et al. and proposed it to be pathogenic
(Mackenzie et al., 2017). We detected an additional missense variant,
suggested to be pathogenic by Mackenzie et al. (p.Ala381Thr, CADD
score 22.4), in one of our investigated controls with inclusion age of
70 years. In total, 3 of the 4missense variants identiﬁed in unaffected
control subjects had a CADD score >20, including the p.Gln318Arg
variant present in 29 of our tested controls (CADD score 23.5).
Despite ours and others’ ambiguous genetic observations (Van
Der Spek et al., 2017), we acknowledge that TIA1 is a promising
functional candidate gene for TDP-related ALS and FTD.
Similar to other ALS and ALS-FTD genes, it encodes an RNA-
binding protein that assembles into stress granules. Mutant TIA1
was shown to alter these stress granule dynamics and, by this, pro-
mote TDP-43 accumulation and aggregation (Mackenzie et al., 2017).
Our ﬁndings in a large European patient-control cohort indicate
that variants in TIA1 are not a common cause of ALS and FTD.
Furthermore, the observation of recurring TIA1 LCD missense var-
iants in unaffected individuals, including variants with estimated
CADD scores >20, together with the lack of signiﬁcant co-
segregation in informative families, lead us to conclude that it is
too early to attribute TIA1 genetic variation to ALS or FTD risk.
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